Prevention of Device Infection: New Implantable Devices

  • Jean-Claude DeharoEmail author
  • Cristian Martignani


Infections related to cardiac implantable electrical devices (CIEDI) represent a relevant issue both for clinical and economic perspective. Since several reports showed an increased incidence of CIEDI in replacement procedures (vs. first implant), many efforts were devoted to improve battery longevity. However, it was early discovered that leads represented the main factor coupled with comorbidities. In this chapter we will start explaining this change in perception. Later we will provide a complete view of the historical perspective of leadless pacing from the very early pioneering experiences until last developments. Moreover, we will discuss pros and cons of the available devices in the light of CIEDI prevention and possible future improvements. The second part of the chapter covers leadless defibrillator describing its role for CIEDI prevention and management (i.e., reimplantation after lead extraction). We will conclude depicting future devices and approaches to provide new effective devices able to completely substitute current transvenous standards.


Pacemaker Defibrillator Leadless Infection Resynchronization Complication Lead Technology Device 


  1. 1.
    Clementy N, et al. Infections and associated costs following cardiovascular implantable electronic device implantations: a nationwide cohort study. Europace. 2018;20(12):1974–80.PubMedGoogle Scholar
  2. 2.
    Voigt A, Shalaby A, Saba S. Rising rates of cardiac rhythm management device infections in the United States: 1996 through 2003. J Am Coll Cardiol. 2006;48(3):590–1.PubMedGoogle Scholar
  3. 3.
    Johansen JB, et al. Higher incidence of pacemaker infection after replacement than after first implantation: experiences from 36,076 consecutive patients. Heart Rhythm. 2006;3(5):S102–3.Google Scholar
  4. 4.
    Diemberger I, et al. From lead management to implanted patient management: indications to lead extraction in pacemaker and cardioverter-defibrillator systems. Expert Rev Med Devices. 2011;8(2):235–55.PubMedGoogle Scholar
  5. 5.
    Moss AJ, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med. 1996;335(26):1933–40.PubMedGoogle Scholar
  6. 6.
    Moss AJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877–83.PubMedGoogle Scholar
  7. 7.
    Bardy GH, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–37.PubMedGoogle Scholar
  8. 8.
    Providencia R., et al. Transvenous implantable cardioverter-defibrillator (ICD) lead performance: a meta-analysis of observational studies. J Am Heart Assoc, 2015:4(11).Google Scholar
  9. 9.
    Maisel WH, Kramer DB. Implantable cardioverter-defibrillator lead performance. Circulation. 2008;117(21):2721–3.PubMedGoogle Scholar
  10. 10.
    Diemberger I, et al. Implantation of cardioverter-defibrillator: effects on shoulder function. Int J Cardiol. 2013;168(1):294–9.PubMedGoogle Scholar
  11. 11.
    Diemberger I, et al. From lead management to implanted patient management: systematic review and meta-analysis of the last 15 years of experience in lead extraction. Expert Rev Med Devices. 2013;10(4):551–73.PubMedGoogle Scholar
  12. 12.
    Sutton R. The first European journal on cardiac electrophysiology and pacing, the European journal of cardiac pacing and electrophysiology. Europace. 2011;13(12):1663–4.PubMedGoogle Scholar
  13. 13.
    Vardas P, et al. A miniature pacemaker introduced intravenously and implanted Endocardially. Preliminary Findings from an Experimental Study. 1991;1:27–30.Google Scholar
  14. 14.
    Greenspon AJ, et al. 16-year trends in the infection burden for pacemakers and implantable cardioverter-defibrillators in the United States 1993 to 2008. J Am Coll Cardiol. 2011;58(10):1001–6.PubMedGoogle Scholar
  15. 15.
    Beurskens NE, Tjong FV, Knops RE. End-of-life Management of Leadless Cardiac Pacemaker Therapy. Arrhythm Electrophysiol Rev. 2017;6(3):129–33.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Dayal N, Burri H. Leadless cardiac stimulation: ready to take Centre stage? 2016;19:83–9.Google Scholar
  17. 17.
    Miller MA, et al. Leadless cardiac pacemakers: back to the future. J Am Coll Cardiol. 2015;66(10):1179–89.PubMedGoogle Scholar
  18. 18.
    Reddy VY, et al. Percutaneous implantation of an entirely intracardiac leadless pacemaker. N Engl J Med. 2015;373(12):1125–35.PubMedGoogle Scholar
  19. 19.
    Reynolds D, et al. A leadless intracardiac transcatheter pacing system. N Engl J Med. 2016;374(6):533–41.PubMedGoogle Scholar
  20. 20.
    Madhavan M, et al. Advances and future directions in cardiac pacemakers: part 2 of a 2-part series. J Am Coll Cardiol. 2017;69(2):211–35.PubMedGoogle Scholar
  21. 21.
    Chew DS, Kuriachan V. Leadless cardiac pacemakers: present and the future. Curr Opin Cardiol. 2018;33(1):7–13.PubMedGoogle Scholar
  22. 22.
    Sperzel J, Hamm C, Hain A. Nanostim-leadless pacemaker. Herzschrittmacherther Elektrophysiol. 2018;29(4):327–33.PubMedGoogle Scholar
  23. 23.
    Lee JZ, Mulpuru SK, Shen WK. Leadless pacemaker: performance and complications. Trends Cardiovasc Med. 2018;28(2):130–41.PubMedGoogle Scholar
  24. 24.
    El-Chami MF, et al. Updated performance of the Micra transcatheter pacemaker in the real-world setting: a comparison to the investigational study and a transvenous historical control. Heart Rhythm. 2018;15(12):1800–7.PubMedGoogle Scholar
  25. 25.
    Martinez-Sande JL, et al. Acute and long-term outcomes of simultaneous atrioventricular node ablation and leadless pacemaker implantation. Pacing Clin Electrophysiol. 2018;41(11):1484–90.PubMedGoogle Scholar
  26. 26.
    Sperzel J, et al. Primary safety results from the LEADLESS observational study. Europace. 2018;20(9):1491–7.PubMedGoogle Scholar
  27. 27.
    Epstein AE, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;51(21):e1–62.PubMedGoogle Scholar
  28. 28.
    Zipes DP, et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J. 2006;27(17):2099–140.PubMedGoogle Scholar
  29. 29.
    Boriani G, Diemberger I. Cardiac resynchronization therapy in the real world: need to upgrade outcome research. Eur J Heart Fail. 2018;20(10):1469–71.PubMedGoogle Scholar
  30. 30.
    Ziacchi M, et al. Cardiac resynchronization therapy: a comparison among left ventricular bipolar, quadripolar and active fixation leads. Sci Rep. 2018;8(1):13262.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Biffi M, et al. Phrenic stimulation: a challenge for cardiac resynchronization therapy. Circ Arrhythm Electrophysiol. 2009;2(4):402–10.PubMedGoogle Scholar
  32. 32.
    Biffi M, et al. Benefits of left ventricular endocardial pacing comparing failed implants and prior non-responders to conventional cardiac resynchronization therapy: a subanalysis from the ALSYNC study. Int J Cardiol. 2018;259:88–93.PubMedGoogle Scholar
  33. 33.
    Auricchio A, et al. Feasibility, safety, and short-term outcome of leadless ultrasound-based endocardial left ventricular resynchronization in heart failure patients: results of the wireless stimulation endocardially for CRT (WiSE-CRT) study. Europace. 2014;16(5):681–8.PubMedGoogle Scholar
  34. 34.
    Reddy VY, et al. Cardiac resynchronization therapy with wireless left ventricular Endocardial pacing: the SELECT-LV study. J Am Coll Cardiol. 2017;69(17):2119–29.PubMedGoogle Scholar
  35. 35.
    Sieniewicz J, et al. Real world experience of leadless LV endocardial CRT with the WiSE CRT pacing system. Int Study. 2018;24:S66.Google Scholar
  36. 36.
    Galand V, et al. An entirely leadless cardiac resynchronization therapy. Eur Heart J. 2019;40(10):858–9.PubMedGoogle Scholar
  37. 37.
    Roberts PR, et al. A leadless pacemaker in the real-world setting: the Micra transcatheter pacing system post-approval registry. Heart Rhythm. 2017;14(9):1375–9.PubMedGoogle Scholar
  38. 38.
    Da Costa A, et al. Transcatheter leadless cardiac pacing: the new alternative solution. Int J Cardiol. 2017;227:122–6.PubMedGoogle Scholar
  39. 39.
    Kypta A, et al. Leadless cardiac pacemaker implantation after Lead extraction in patients with severe device infection. J Cardiovasc Electrophysiol. 2016;27(9):1067–71.PubMedGoogle Scholar
  40. 40.
    Koay A, et al. Treating an infected transcatheter pacemaker system via percutaneous extraction. Heart Rhythm Case Rep. 2016;2(4):360–2.Google Scholar
  41. 41.
    Boriani G, et al. Expenditure and value for money: the challenge of implantable cardioverter defibrillators. QJM. 2009;102(5):349–56.PubMedGoogle Scholar
  42. 42.
    Merchant FM, et al. Implantable Cardioverter-defibrillators at end of battery life: opportunities for risk (re)-stratification in ICD recipients. J Am Coll Cardiol. 2016;67(4):435–44.PubMedGoogle Scholar
  43. 43.
    Ezzat VA, et al. A systematic review of ICD complications in randomised controlled trials versus registries: is our ‘real-world’ data an underestimation? Open Heart. 2015;2(1):e000198.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Kleemann T, et al. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of >10 years. Circulation. 2007;115(19):2474–80.PubMedGoogle Scholar
  45. 45.
    Dorwarth U, et al. Transvenous defibrillation leads: high incidence of failure during long-term follow-up. J Cardiovasc Electrophysiol. 2003;14(1):38–43.PubMedGoogle Scholar
  46. 46.
    Bardy GH, et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med. 2010;363(1):36–44.PubMedGoogle Scholar
  47. 47.
    Burke MC, et al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE study and EFFORTLESS registry. J Am Coll Cardiol. 2015;65(16):1605–15.PubMedGoogle Scholar
  48. 48.
    Gold MR, et al. Subcutaneous implantable cardioverter-defibrillator post-approval study: clinical characteristics and perioperative results. Heart Rhythm. 2017;14(10):1456–63.PubMedGoogle Scholar
  49. 49.
    Lambiase PD, et al. Worldwide experience with a totally subcutaneous implantable defibrillator: early results from the EFFORTLESS S-ICD registry. Eur Heart J. 2014;35(25):1657–65.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Ahmed FZ, et al. Totally leadless dual-device implantation for combined spontaneous ventricular tachycardia defibrillation and pacemaker function: a first report. Can J Cardiol. 2017;33(8):1066 e5–7.Google Scholar
  51. 51.
    Erath JW, et al. Epicardial CRT-P- and S-ICD implantation in a young patient with persistent left superior vena cava. Herzschrittmacherther Elektrophysiol. 2016;27(4):396–8.PubMedGoogle Scholar
  52. 52.
    El-Chami MF, et al. Outcome of subcutaneous implantable cardioverter defibrillator implantation in patients with end-stage renal disease on Dialysis. J Cardiovasc Electrophysiol. 2015;26(8):900–4.PubMedGoogle Scholar
  53. 53.
    Koman E, et al. Outcomes of subcutaneous implantable cardioverter-defibrillator implantation in patients on hemodialysis. J Interv Card Electrophysiol. 2016;45(2):219–23.PubMedGoogle Scholar
  54. 54.
    De Maria E, et al. Prevention of infections in cardiovascular implantable electronic devices beyond the antibiotic agent. J Cardiovasc Med (Hagerstown). 2014;15(7):554–64.Google Scholar
  55. 55.
    Maurizi N, et al. Effectiveness of subcutaneous implantable cardioverter-defibrillator testing in patients with hypertrophic cardiomyopathy. Int J Cardiol. 2017;231:115–9.PubMedGoogle Scholar
  56. 56.
    Friedman DJ, et al. Ventricular fibrillation conversion testing after implantation of a subcutaneous implantable cardioverter defibrillator: report from the national cardiovascular data registry. Circulation. 2018;137(23):2463–77.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Migliore F, et al. Subcutaneous implantable cardioverter defibrillator in patients with arrhythmogenic right ventricular cardiomyopathy: results from an Italian multicenter registry. Int J Cardiol. 2019;280:74–9.PubMedGoogle Scholar
  58. 58.
    Ferrero P, et al. Entirely subcutaneous defibrillator and complex congenital heart disease: data on long-term clinical follow-up. World J Cardiol. 2017;9(6):547–52.PubMedPubMedCentralGoogle Scholar
  59. 59.
    D’Souza BA, et al. Outcomes in patients with congenital heart disease receiving the subcutaneous implantable-cardioverter defibrillator: results from a pooled analysis from the IDE study and the EFFORTLESS S-ICD registry. JACC Clin Electrophysiol. 2016;2(5):615–22.PubMedGoogle Scholar
  60. 60.
    Brouwer TF, et al. Long-term clinical outcomes of subcutaneous versus Transvenous implantable defibrillator therapy. J Am Coll Cardiol. 2016;68(19):2047–55.PubMedGoogle Scholar
  61. 61.
    Friedman DJ, et al. Trends and in-hospital outcomes associated with adoption of the subcutaneous implantable cardioverter defibrillator in the United States. JAMA Cardiol. 2016;1(8):900–11.PubMedPubMedCentralGoogle Scholar
  62. 62.
    Honarbakhsh S, et al. A propensity matched case-control study comparing efficacy, safety and costs of the subcutaneous vs. transvenous implantable cardioverter defibrillator. Int J Cardiol. 2017;228:280–5.PubMedGoogle Scholar
  63. 63.
    Kobe J, et al. Implantation and follow-up of totally subcutaneous versus conventional implantable cardioverter-defibrillators: a multicenter case-control study. Heart Rhythm. 2013;10(1):29–36.PubMedGoogle Scholar
  64. 64.
    Mithani AA, et al. Characteristics and early clinical outcomes of patients undergoing totally subcutaneous vs. transvenous single chamber implantable cardioverter defibrillator placement. Europace. 2018;20(2):308–14.PubMedGoogle Scholar
  65. 65.
    Basu-Ray I, et al. Subcutaneous versus Transvenous implantable defibrillator therapy: a meta-analysis of case-control studies. JACC Clin Electrophysiol. 2017;3(13):1475–83.PubMedGoogle Scholar
  66. 66.
    Winter J, et al. Intermuscular technique for implantation of the subcutaneous implantable cardioverter defibrillator: long-term performance and complications. Europace. 2017;19(12):2036–41.PubMedGoogle Scholar
  67. 67.
    Migliore F, et al. Intermuscular two-incision technique for subcutaneous implantable cardioverter defibrillator implantation: results from a multicenter registry. Pacing Clin Electrophysiol. 2017;40(3):278–85.PubMedGoogle Scholar
  68. 68.
    Droghetti A, et al. Ultrasound-guided serratus anterior plane block combined with the two-incision technique for subcutaneous ICD implantation. Pacing Clin Electrophysiol. 2018;41(5):517–23.PubMedGoogle Scholar
  69. 69.
    Boersma L, et al. Infection and mortality after implantation of a subcutaneous ICD after transvenous ICD extraction. Heart Rhythm. 2016;13(1):157–64.PubMedGoogle Scholar
  70. 70.
    Viani S, et al. Use and outcomes of subcutaneous implantable cardioverter-defibrillator (ICD) after transvenous ICD extraction: an analysis of current clinical practice and a comparison with transvenous ICD reimplantation. Heart Rhythm. 2019;16(4):564–71.PubMedGoogle Scholar
  71. 71.
    Boveda S, et al. Use of leadless pacemakers in Europe: results of the European heart rhythm association survey. Europace. 2018;20(3):555–9.PubMedGoogle Scholar
  72. 72.
    Markets, R.a., Global Leadless Cardiac Pacemakers Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026.Google Scholar
  73. 73.
    Boriani G, Elsner C, Diemberger I. The struggle against infections of cardiac implantable electrical devices: the burden of costs requires new personalized solutions. Europace. 2018;20(12):1877–9.PubMedGoogle Scholar
  74. 74.
    Bereuter L, et al. Leadless dual-chamber pacing: a novel communication method for wireless pacemaker synchronization. JACC Basic Transl Sci. 2018;3(6):813–23.PubMedPubMedCentralGoogle Scholar
  75. 75.
    Bereuter L., et al. Leadless cardiac resynchronization therapy: an in vivo proof-of-concept study of wireless pacemaker synchronization. Heart Rhythm, 2019.Google Scholar
  76. 76.
    Hwang GT, et al. Self-powered cardiac pacemaker enabled by flexible single crystalline PMN-PT piezoelectric energy harvester. Adv Mater. 2014;26(28):4880–7.PubMedGoogle Scholar
  77. 77.
    Corazza I, et al. Wireless Endocardial atrial (and ventricular) sensing with no implanted power source: a proposal. J Med Syst. 2019;43(6):159.PubMedGoogle Scholar
  78. 78.
    Marban E, Cho HC. Biological pacemakers as a therapy for cardiac arrhythmias. Curr Opin Cardiol. 2008;23(1):46–54.PubMedGoogle Scholar
  79. 79.
    Robinson RB. Engineering a biological pacemaker: in vivo, in vitro and in silico models. Drug Discov Today Dis Models. 2009;6(3):93–8.PubMedPubMedCentralGoogle Scholar
  80. 80.
    Hu YF, et al. Biological pacemaker created by minimally invasive somatic reprogramming in pigs with complete heart block. Sci Transl Med. 2014;6(245):245ra94.PubMedPubMedCentralGoogle Scholar
  81. 81.
    Neuzil P, First-in-man Feasibility Study Of Subcutaneous Defibrillation Utilizing An Integrated Flexible String Shaped Defibrillator. Heart Rhythm Society Congress (Chicago) Session C-LBCT03–01 - 12.05.2017, 2017.Google Scholar
  82. 82.
    Tjong FVY, Koop BE. The modular cardiac rhythm management system: the EMPOWER leadless pacemaker and the EMBLEM subcutaneous ICD. Herzschrittmacherther Elektrophysiol. 2018;29(4):355–61.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Service de CardiologieCHU La TimoneMarseilleFrance
  2. 2.Faculté de Médecine NordAMU, UMR MD2MarseilleFrance
  3. 3.Department of Cardiology, Institute of Cardiology, S. Orsola-MalpighiS. Orsola Malpighi Hospital, University of BolognaBolognaItaly

Personalised recommendations